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SUMMARY
CD32 has raised conflicting results as a putative marker of the HIV-1 reservoir.
We measured CD32 expression in tissues from viremic and virally suppressed hu-
manized mice treated relatively early or late after HIV-1 infection with combined
antiretroviral therapy. CD32 was expressed in a small fraction of the memory
CD4+ T-cell subsets from different tissues in viremic and aviremicmice, regardless
of treatment initiation time. CD32+ memory CD4+ T cells were enriched in cell-
associated (CA) HIV-1 DNA but not in CA HIV-1 RNA as compared to the
CD32CD4+ fraction. Using multidimensional reduction analysis, several memory
CD4+CD32+ T-cell clusters were identified expressing HLA-DR, TIGIT, or PD-1.
Importantly, although tissue-resident CD32+CD4+ memory cells were enriched
with translation-competent reservoirs, most of it was detected in memory
CD32-CD4+ T cells. Our findings support that CD32 labels highly activated/ex-
hausted memory CD4+ T-cell subsets that contain only a small proportion of the
translation-competent reservoir.
INTRODUCTION
The advent of combined antiretroviral therapy (cART) has dramatically improved the clinical care of HIV-1
infection. Since the START trial demonstrated that immediate initiation of cART is superior in reducing
serious acquired immunodeficiency syndrome (AIDS)- and non-AIDS-related events (Lundgren et al.,
2015), treatment guidelines advise to start therapy as early as possible (Panel on Antiretroviral Guidelines
for Adults and Adolescents, 2017). Although beneficial in reduction of morbidities, early treatment started
even during acute infection is not curative due to the establishment of long-lived viral reservoirs (Chun
et al., 1998; Archin et al., 2012; Deng and Siliciano, 2014; Colby et al., 2018). Viral reservoirs, quantified
by total HIV-1 DNA, are generally described as all cells infected with HIV-1, irrespective of their replication
status or competence (Avettand-Fenoel et al., 2016). Viral persistence of replication-competent HIV-1 un-
der cART, on a timescale of years, is however attributed to the latent portion of viral reservoirs. Therefore,
using a practical definition (Eisele and Siliciano, 2012), latently infected cells that contain dormant but repli-
cation-competent provirus and are capable to resume viral production at a future time point represent the
HIV-1 reservoir.
Latently infected cells have a half-life of 43.9 months, whichmakes them extremely resistant to antiretroviral
therapy (ART). Therefore, discontinuation of treatment will, with great certainty, be followed by a viral
rebound. The establishment of HIV-1 reservoirs occurs very rapidly upon primary infection. In simian immu-
nodeficiency virus, reservoirs are found as early as three days post-infection in various tissues, even before
virus detectability in circulation (Whitney et al., 2014). Likewise, in humans, initiation of cART during the
acute phase of infection does not impede reservoir formation (Chun et al., 1998; Colby et al., 2018). Latent
reservoirs are extremely stable with an estimated half-life of 43.9 months. This significantly hinders cART
ability to eliminate HIV-1 within a patient’s lifetime, with viral rebound highly likely to happen after treat-
ment interruption (Siliciano et al., 2003b; Besson et al., 2014; Buzon et al., 2015; Crooks et al., 2015). The
frequency of latently infected cells is very low (approximately 1 in 105-108 of CD4+ T cells) (Finzi et al.,
1997; Siliciano et al., 2003a; Strain et al., 2005), resulting in enormous technical challenges to precisely
determine and study HIV-1 latency. Originally, the highest frequency of latently infected cells was thought
to be localized in resting central memory CD4+ T cells (Chomont et al., 2009; Descours et al., 2012; Sáez-
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Cirión et al., 2013), but its heterogeneous dissemination over various CD4+ T-cell memory subsets has been
now recognized (Buzon et al., 2014; Banga et al., 2016; Zerbato et al., 2019; Kwon et al., 2020). In addition,
the tissue distribution of reservoirs is diverse and poorly reflected by recirculating CD4+ T cells in peripheral
blood (Blum and Pabst, 2007; De Scheerder et al., 2019). Against this background, the characterization of
cellular biomarkers of latently infected cells would enormously facilitate the development of strategies for
their targeted depletion.
Various surface markers (CXCR3, CCR6, CD2, PD-1, LAG-3, TIGIT) were proposed to identify latently in-
fected CD4+ T cells but studies have not converged (Iglesias-Ussel et al., 2013; Anderson et al., 2014; Banga
et al., 2018; Fromentin et al., 2016; Gosselin et al., 2017). The Fc-g-RII receptor CD32 was recently proposed
as a putative marker of cells highly enriched for total HIV-1 DNA and for replication-competent provirus
(Descours et al., 2017). These findings have attracted a lot of attention but some recent works have relin-
quished inconclusive results (Abdel-Mohsen et al., 2018; Bertagnolli et al., 2018; Martin et al., 2018;
Noto et al., 2018). CD32+ CD4+ T cells were shown to harbor a higher activation profile and to correlate
with general immune activation. Overall, data from several patient cohorts did not substantiate the rele-
vance of CD32 expression in latent HIV-1 reservoir probably due to the heterogeneity of cART initiation’s
timing, cART duration, and levels of immune activation. Recently, the different purity of CD32+CD4+ T cells
across various studies was proposed as a possible explanation for these divergent findings (Abdel-Mohsen
et al., 2018; Darcis et al., 2019). Furthermore, only few studies have scrutinized the role of CD32 in tissues
(Noto et al., 2018; Cantero-Pérez et al., 2019; Thornhill et al., 2019).
Molecular mechanisms of HIV-1 latency have been mainly studied in cell lines, but these data have very
limited relevance within clinical settings (Han et al., 2007; Van Lint, Bouchat and Marcello, 2013; Whitney
and Brad Jones, 2018). Instead, humanized mice models have earned their place in HIV-1 research as ver-
satile tools to study HIV-1 pathogenesis in vivo (Marsden and Zack, 2017). To date, cART treatment has re-
produced the features of HIV-1 latency in these small animals (Marsden et al., 2017; Satheesan et al., 2018).
The advantages of such models are the easy access to all anatomical sites and the precise control over
timing and duration of treatment allowing a detailed understanding of HIV-1 latency under various
conditions.
We have developed an HIV-1 latency model in humanized Nonobese diabetic/Severe Combined Immuno-
Deficient gamma (NSG) mice to investigate the early establishment of the viral reservoir in untreated, early
(one week after HIV-1 infection), and late treated mice (seven weeks after HIV-1 infection) with cART. Our
study examined the expression of CD32 as a marker of viral reservoirs in memory CD4+T cells with capa-
bilities of long-term persistence and its relationship to immune activation. Using a strict flow cytometry
gating strategy, we show here that CD32 expression was low in CD4+ T cells from different tissues in hu-
manized mice treated early or late and was mostly due to the expression of the CD32a isoform.
CD32+CD4+ memory T cells were enriched in cell-associated HIV-1 DNA (CA HIV-1 DNA) but not in cell-
associated HIV-1 RNA (CA HIV-1 RNA), indicating HIV latency in these cells. CD32+CD4+ memory subsets
were associated with their activation/exhaustion status under cART, and cluster analysis revealed that
CD32+CD4+ memory cells are phenotypically related to cells expressing HLA-DR, PD-1, or TIGIT. Impor-
tantly, most of the p24 productive reservoir upon latency reversal was situated in the CD32- memory
CD4+ T cell fraction. Taken together, our data indicate that CD32 expression describes activated CD4+
T-cell memory subsets enriched for proviral DNA independently of treatment initiation. Ultimately, we
showed here that CD32 does not clearly label the translation-competent HIV-1 reservoir that needs to
be eliminated in the perspective of HIV-1 cure.
RESULTS
Early cART treatment leads to faster viral suppression than late treatment in humanized mice
In this study, NSG mice were ‘‘humanized’’ with CD34+ hematopoietic stem cells over 24 weeks and then
infected with HIV-1 JR-CSF Infectious Molecular Clone (pYK-JRCSF). One group was left untreated, a sec-
ond group was treated early (one week after HIV-1 infection), and a third group was treated late (seven
weeks after HIV-1 infection) (Figure 1).
In each group, oral treatment was maintained for eight weeks. As expected, in all conditions, a sharp in-
crease of plasma HIV-1 RNA in the range of 104-105 copies per ml was detected during the first week after
infection (Figure 2A). Subsequently, plasma viremia was strongly reduced within two weeks of either early
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or late treatment. Interestingly, early treatment led to a significantly quicker viral suppression (i.e. undetect-
ability of the viral load) (p < 0.0001, Figure 2C). Conversely, the kinetics of viral rebound after treatment
interruption were similar for both treatment groups (Figure 2D). Importantly, we observed that a portion
of early treated mice rebounded only transiently (four out of fifteen or 26.7%) with ‘‘spontaneous’’ viral sup-
pression up to six weeks after treatment cessation, whereas this ‘‘secondary control’’ phenomenon was not
observed in the late treated group (Figures S1A and S1B). We measured HIV-1 RNA in the bone marrow,
spleen, and lymph nodes of early treated mice as compared to untreated viremic mice after one week of
HIV-1 infection. Viral loads were almost undetectable in the bone marrow of the treated mice, whereas
some ongoing HIV-1 replication still occurs in the spleen and in the lymph nodes as shown by a detectable
viral load in these two tissues (Figures S1C and S1D). Taken together, these observations indicate the
establishment of replication-competent viral reservoirs within one week of infection in this model.
The immunological hallmark of HIV-1 infection is the depletion of CD4+ T cells. As expected, we observed a
rapid decline in circulating CD4+ T cells upon infection. At week three post-infection, untreated mice lost
around one third of their human CD4+ T cells, whereas early treatment prevented CD4+ T-cell loss (Fig-
ure 2B). Late treatment onset allowed a gradual recovery of CD4+ T cells. At the endpoint (week sixteen),
the late treated mice showed peripheral blood CD4+ T-cell counts restored to similar levels when
compared to the early treated mice (Figure 1). In agreement with our findings from peripheral blood (Fig-
ure 2B), the relative number of human CD4+ T cells was also significantly increased by cART in the spleen for
both treatment groups (Figures S2 and 2A). These data suggest recovery of the human CD4+ T-cell
compartment even after late cART onset in our model.
Total HIV-1 DNA and T-cell exhaustion are significantly reduced by early cART treatment
The stable persistence of provirus during therapy is a defining factor of HIV-1 latency. Therefore, we
analyzed three different organ sites (bone marrow, lymph nodes, and spleen) for the presence of CA
HIV-1 DNA by droplet digital Polymerase Chain Reaction (ddPCR), either at the end of cART treatment
or corresponding time points for the non-treated animals (see experimental design in Figure 1). cART
led to a significant reduction of CA HIV-1 DNA compared to the untreated control group (Figure 3A).
Furthermore, early initiation of cART significantly reduced CA HIV-1 DNA as compared to late initiation
in bone marrow (1.82 and 3.85 median log10 copies/million cells, respectively) and lymph nodes (2.45
and 3.7 median log10 copies/million cells, respectively), with a similar but non-significant trend observed
in the spleen. These data underline that humanized mice mimic reservoir establishment and persistence
during cART treatment similar to humans.
Figure 1. Design of the Study
One hundred twenty humanized NSG mice were infected with HIV-1 JRCSF. At week one post-infection, the cART regimen was initiated (n = 58) in the early
treated group and sustained for twomonths. Late treatment was started at seven weeks post-infection (n = 42) and continued for twomonths. In each group,
a number of animals were sacrificed at the end of treatment, corresponding to week nine for early treated (n = 43) and to week fifteen for late treated (n = 34)
animals. The untreated group (n = 20) never received cART and was euthanized correspondingly to the sacrifices of both treatment groups (week nine for
early treated andweek fifteen for late treatedmice). Viral rebound after treatment interruption wasmonitored for the remaining early (n = 15) and late treated
(n = 8) animals for a duration of six weeks or longer if animals were not detectable for HIV-1 viral load.
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Infection with HIV-1 induces not only loss of CD4+ T cells in humans but also long-term alterations of the
activation status in CD4+ and CD8+ T cells which persist during cART (Hazenberg et al., 2000; Hunt
et al., 2003). In our humanized mice model, we assessed T-cell phenotypes in the tissues at the end of treat-
ment and corresponding time points for untreated animals by flow cytometry. The expression of the
exhaustion markers PD-1 and TIGIT was decreased by cART treatment on both CD4+ and CD8+ T cells,
but the decrease was only significant between untreated and early treated groups (Figures 3B and 3C).
Interestingly, the activation marker HLA-DR showed no difference among groups (Figures 3B and 3C). In
addition, we observed a normalization of CD27 expression on CD4+ T cells by both treatment regimens
(Figures S2B), suggesting a recovery in T-cell differentiation in our humanized mice model.
CD32+CD4+ memory T-cells do not contain T-B cell conjugates and harbor higher amounts of
CA HIV-1 DNA but not of HIV-1 CA RNA
Next, we investigated the expression of CD32, a proposed marker of the HIV-1 reservoir. Given the previ-
ously reported technical difficulties to obtain pure CD32+CD4+ T cells (Martin et al., 2018; Osuna et al.,
2018; Pérez et al., 2018), we applied an elaborated flow cytometry gating strategy to isolate CD4+ memory
T cells (defined as CD45RA) excluding doublets. To preclude contaminations by doublets, B cells or
monocytes, strict singlet gating (on area versus width for forward and side scatter), as well as exclusion
of CD19 and CD14 signals, were performed to analyze and sort CD32+CD4+ T cells by flow cytometry (Fig-
ure S3). The mean post-sorting purity of the CD32+CD4+ T cells was 98.8% of CD4+ T-cell singlets (Fig-
ure S4). We observed also that human CD4+ T cells contained a CD32 dim population with low expression
of CD32 in contrast to a CD32 bright population expressed in CD19+ B cells and T-B cell doublets or conju-
gates (Figure S5A). We next investigated whether T-B cell trogocytosis was involved as previously reported
(Martin et al., 2018; Osuna et al., 2018; Thornhill et al., 2019) by using image cytometry on CD32+ CD4+
CD45RA memory sorted T cells of humanized mice and of HIV-1-infected patients. CD32+CD4+ memory
T cells contained no doublets, T-B cell conjugates, or B cell/monocyte contaminations (manual viewing of
sorted cell images, data not shown). CD32 expression was localized in small, concentrated areas of CD4+
T cells (Figures 4A and 4C) in contrast to sorted B cells on which CD32 was distributed homogeneously over
the cell membrane (Figures 4B and 4D). Of note, no signal of CD19 or CD20 expression was detected on
Figure 2. Early Treatment Significantly Decreased Time to Viral Suppression
(A and B) (A) Plasma viral load of early treated (n = 43), late treated (n = 34), and untreated (n = 20) mice and (B) percentage
of CD4+ T cells were determined every two weeks in peripheral blood. Background coloring of graphs highlights
treatment periods: light green for early treatment, violet for late treatment, dark green is obtained by a two-week overlap
(week seven to week nine) of early and late treatment periods (figure A and B).
(C and D) (C) Time to viral suppression (median two and four weeks, respectively) (p < 0.0001) and (D) viral rebound (p =
0.107) for the early and late group. Statistical analysis was executed using Mantel COX rank test. (***p < 0.005; ns,
nonsignificant test p > 0.05).
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CD32+CD4+ T cells (Figures 4A and 4C). Importantly, overlay images emphasize that CD32 expression is
rooted in small, non-CD4+ T-cell compartments attached to CD4+ T cells (Figures 4E and 4F). To explore
if other cell types known to closely interact with CD4+ T cells might be the source of these CD32 expressing
fragments attached to the CD4+ T cells, we used flow cytometry in peripheral blood mononuclear cells
(PBMCs) of two HIV-1-infected patients treated with cART for at least two years and we did not exclude
B or CD14+ cells as previously done. We detected different lineage markers coexpressed on CD32+
CD4+ T cells that could explain the origin of the attached fragments (potential trogocytosis): between
30 and 39% of HLADR (Human Leukocyte Antigen – DR isotype) + CD19+ B cells, around 1% of NK cells
(CD4+CD16 + HLADR+), 4% of monocytes (all CD14+ cells), and up to 1% of dendritic cells (CD11c+).
Around 7% of CD32+ CD4+ T cells were expressing HLA-DR, and this expression was not provided by
CD19+ B cells, CD11c+, or CD16+ cells. Therefore, as we excluded B cells and monocytes in our strict
flow cytometry strategy in this study, the fragments attached to the CD4+ T cells might come from other
antigen-presenting cells (APCs) or NK cells. Furthermore, we measured the mRNA expression of CD32a
and CD32b by real-time PCR in sorted CD32+CD4+CD45RAT cells and in a pool of CD14+ and CD19+ cells
that were excluded by our flow cytometry gating strategy. CD32+ CD4+ CD45RA memory T cells ex-
pressed mainly CD32a and low levels of CD32b mRNA, whereas both CD32a and CD32b mRNA were ex-
pressed in the pool of CD14+ and CD19+ cells (Table 1), confirming the exclusion of B cells in our purified
CD32+CD4+ memory T cells.
Figure 3. cART Significantly Decreased Total HIV-1 DNA in Peripheral Organs and HIV-1-Related Immune
Exhaustion and Activation on Human T Cells
(A) Total HIV-1 DNA quantified from the bone marrow, lymph nodes, and spleen is represented for early treated (n = 9),
late treated (n = 11), and untreated mice (n = 6). Percentages of cells expressing the respective markers PD-1, TIGIT, and
HLA-DR on CD4+ T cells (B) and CD8+ T cells (C) extracted from the spleen at experimental endpoint (median age of nine
months, eight weeks total cART duration for both treatment groups) are depicted for early treated mice (n = 17), late
treated mice (n = 23), and untreated mice (n = 16). Statistical testing was performed using non-parametric Kruskal-Wallis
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When assessing the expression pattern of the memory CD32+CD4+ T cells in the different groups of mice,
we found that overall CD32 cell surface expression did not differ substantially across various tissues nor be-
tween treatment groups (Figures S6A–S6D). Only lymph node T cells from healthy mice had significantly
lower CD32 expression when compared to the untreated group (Figures S6 and 6D). Importantly, we did
not find any difference during longitudinal sampling in the spleen (Figure S5B). To determine whether
CD32 expressing cells were enriched for total CA HIV-1 DNA or RNA in cART-suppressed mice, CD32-
and CD32+ were flow sorted from the CD4+ memory (i.e. CD45-) T cells. A sufficient quantity of
CD32+CD4+ memory T cells were only obtained from the bone marrow and spleen. Memory
Figure 4. CD32 Is Expressed on Cell Fragments Attached to CD4+ T Cells with No Signs of T-B Cell Trogocytosis
To assess whether the expression of CD32 on CD4+ T cell comes from T cells or T-B cell conjugates, imaging flow cytometry was performed on sorted
CD32+CD4+ T cells (A, C, E, and F) or sorted CD19+ B cells (B and D) isolated from the spleen of cART suppressed HIV-1-infected humanized mice (A, B, E) or
peripheral blood mononuclear cells (PBMCs) from cART suppressed HIV-1-infected patients (C, D, and F). Flow sorted B cells from humanized mice or
patients were stained, acquired, and represented with the same settings and experimental procedures and,hence, serve as reference population with regard
to CD32, CD19 ,and CD20 signal on images (B, D). Overlay shots of CD4 and CD32 signals of splenocytes from a humanized mouse (E) and of PBMCs from
one HIV-1-infected patient (F).
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CD32+CD4+ T cells harbored significantly higher levels of HIV-1 DNA as compared to their CD32 negative
counterparts (Figures 5A and 5B) in the spleen (4.35 vs 3.51 median log10 copies of HIV-1 DNA per million
cells, respectively, p < 0.01) and in the bone marrow (4.42 vs 3.55 median log10 HIV-1 DNA copies per
million cells, respectively, p < 0.05). Next, we quantified CA HIV-1 RNA but only 14 spleen-derived samples
could be included due to low total RNA yield from CD32+CD4+ T cells. Although we used a limited set of
sampling, we observed no difference for CA HIV-1 RNA between the CD32+CD4+ and the CD32CD4+
memory subsets of the spleen (Figure 5C) (11.52 versus 45.16 median copies of CA RNA per million cells)
for all mice with a detectable viral load.
CD32 is expressed on highly activated memory CD4+ T cells and its level of expression does
not correlate with the HIV-1 total DNA
Next, we assessed whether CD32+CD4+ T cells from tissue lymphocytes showed a particular activation/
exhaustion profile as recently suggested (Badia et al., 2018). We found a significant upregulation of
HLA-DR and PD-1 expression but not of the immune checkpoint marker TIGIT in CD32+CD4+ memory
T cells (Figures 6A–6C), as compared to their CD32- counterparts. This trend was observed in both early
(p < 0.05) and late treatedmice (p < 0.001). We also measured the expression of the early and late activation
markers CD69, HLA-DR, and CD38 (all combined in one channel) of the flow sorted CD32+ and CD32-CD4+
memory T cells. A median of 80% CD32+CD4+ memory T cells expressed at least one of these activation
markers as compared to a median of only 7% CD32CD4+ memory T cells (Figure 6D). Moreover, the geo-
metric mean fluorescence intensity (GMFI) of CD32 correlated moderately with the cumulated GMFI of the
three activation markers (Spearman correlation, p value = 0.0004, r = 0.6872) (Figure 6E). In contrast, there
was no correlation between CD32 expression and the total HIV-1 DNA content in CD4+ T cells (data not
shown, p value = 0.5809, r = 0.2167).
Mouse ID BM Spleen Sorted cell fraction Ct values DCT value against
GAPDH
CD32a CD32b GAPDH CD32a CD32b
S789 X Pool of CD19+ and CD14+ cells 32,36 31,92 24,65 7,71 7,28
S803 X Pool of CD19+ and CD14+ cells 28,86 30,4 21,76 7,1 8,63
S804 X Pool of CD19+ and CD14+ cells 34,45 33,7 25,18 9,27 8,51
S789 x Pool of CD19+ and CD14+ cells 34,51 32,91 27,92 9,59 4,98
S803 x Pool of CD19+ and CD14+ cells 28,99 30,04 25,25 3,73 4,79
S804 x Pool of CD19+ and CD14+ cells 32,35 30,9 26 6,35 4,9
S789 x CD32-CD4+ memory T cells 36,58 37,14 25,07 11,51 12,7
S803 x CD32-CD4+ memory T cells 36,67 36,09 25,36 11,3 10,73
S804 x CD32-CD4+ memory T cells 36,23 37,61 25,97 10,26 11,64
S789 x CD32-CD4+ memory T cells 39,48 38,31 27,73 11,75 10,58
S803 x CD32-CD4+ memory T cells 36,75 36,79 25,37 11,38 11,41
S804 x CD32-CD4+ memory T cells 36,67 36,69 24,81 11,86 11,88
S789, S803, and S804 pooled x CD32 + CD4+ memory T cells 32,14 36,72 26,69 5,45 10,02
S789, S803, and S804 pooled x CD32 + CD4+ memory T cells 34,21 38,82 28,74 5,47 10,08
PCR-negative controls UND UND UND NA NA
Table 1. Gene expression of CD32a and CD32bmRNA isoforms of sorted CD45RACD32CD4+ T cells and a pool of CD19+ and CD14+ cells isolated
from 3 single virally suppressed humanized mice (S789, S803, S804) and sorted CD45RA+CD32+CD4+ T cells pooled from the 3 virally suppressed
humanized mice
Results were analyzed against the GADPH Ct value. UND, undetectable; N/A, not available.
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We next performedmultidimensional single-cell analysis using flow cytometry to investigate the activation/
exhaustion co-expression patterns of the CD32+CD4+ memory T cells. CD32+CD4+ memory T cells were
analyzed in untreated viremic mice (untreated [UT] mice, after four and eight weeks of HIV-1 infection)
and in virally suppressed treated mice after four and eight weeks of cART treatment for both early (early
treated [ET] mice) and late treated (late treated [LT] mice) groups. Co-expression of the markers was
analyzed using the unsupervised algorithmic technique Flow Self-OrganizingMap (FlowSOM). The clusters
defined by FlowSOM (Figure 7A) were organized in a two-way hierarchical heatmap to determine their rela-
tionship (Figure 7B). Statistical analysis of the differential enrichment of clusters at week 4 and 8 revealed
major changes in mice undergoing late treatment. Six clusters belonging to the central effector memory
CD4 metacluster (metacluster number 8) showed an increase at week 8. The majority of these clusters ex-
pressed HLA-DR and in one we observed the expression of CD32 (cluster 6). Overall, clustering identified
three CD4+ T-cell populations harboring CD32 expression that showed a significant increase at week 8 in
early treated mice (ET clusters 3, 11, 21) and one CD4+CD32+ cluster demonstrating a similar increase in
late treated mice (LT clusters 6). Cluster 9 and 47 in LT mice were the unique CD4+CD32+ clusters showing
a decrease at week 9. No significant changes were observed in UT mice. These memory CD4+ clusters ex-
pressed either CD32dim alone (ET cluster 21) or CD32dim HLA-DRhigh expression (ET cluster 3) or CD32dim
HLA-DRhigh and PD-1low expression (LT cluster 6) or CD32dim HLA-DRdim TIGIThigh PD-1dim expression (ET
cluster 11) or CD32high HLA-DRdim TIGITdim PD-1high expression (LT cluster 9) (Figure 7B). Only one naive
CD8+CD32+ cluster harboring HLA-DRhigh expression was detected in CD8+ T cells in late treated mice
(LT cluster 47). These data showed the presence of phenotypically related activated or exhausted subsets
in the memory CD4+ CD32+ T cells in the cART-treated mice when compared to their untreated counter-
part. Overall, the expression of CD32 in these clusters was always associated with another activation (HLA-
DR) or exhaustion marker (PD1, TIGIT), demonstrating that CD32 labeled a highly activated part of the
memory CD4+ T cells.
Tissue-resident memory CD32CD4+ T cells contain most of the translation-competent virus
producing p24
Finally, we sought to answer whether CD32+CD4+memory T cells contained the inducible translation-
competent HIV-1 by assessing p24 production after phorbol myristate acetate (PMA)/ionomycin activation
in the presence of raltegravir and lamivudine to prevent viral spread. Interestingly, more than 95% of p24
producing cells were detected in the CD32-negative fraction from the spleen in both viremic and virally
suppressed mice (Figure 8B). Nevertheless, CD32+CD4+ memory T cells harbored a higher frequency of
p24-positive cells when compared to CD32CD4+ memory T cells suggesting a relative enrichment, as re-
ported for total HIV-1 DNA (Figure 8C). Furthermore, we found higher levels of activation/exhaustion
Figure 5. Total HIV-1 DNA Is Higher in CD32+CD4+ Memory T Cells in the Spleen and the Bone Marrow
Total HIV-1 DNA from flow sorted CD3+CD4+CD45RA T cells according to CD32 expression in bone marrow (A) and
spleen (B) in virally suppressed mice (mixed from early and late treatment conditions) (bone marrow n = 11, spleen n = 10)
depicted as aligned dot plots of individual measurements (CD32- in black circles and CD32 + in red squares). The flow
gating strategy is depicted in Figure S3. (C) HIV-1 CA RNA in flow sorted CD4+memory T cells (CD32- (n = 9) CD32+ (n = 5))
from virally suppressed mice (mixed from early and late treatment conditions). Statistical testing was done using non-
parametric paired Wilcoxon rank tests (A and B) or non-paired tests (C). Exact p values for HIV-1 DNA: bone marrow,
0.0278; spleen, 0.0039, (*p < 0.05. **p < 0.01).
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markers on CD32+CD4+ memory T cells producing p24 than their CD32- counterpart, but this was signifi-
cant only for PD1 (Figure 8D).
DISCUSSION
HIV-1 persists in a pool of latently infected CD4+ T cells, which constitutes a major barrier to curing HIV-1
(Katlama et al., 2013). Early studies found that this reservoir is mainly localized in CD4+ resting T-cell mem-
ory subsets (Chomont et al., 2009) but recent evidence has substantiated on its wide spread distribution
over various compartments of CD4+ T cells (Buzon et al., 2014; Khoury et al., 2016; Hiener et al., 2017; Zer-
bato et al., 2019; Kwon et al., 2020). A number of strategies aiming at reducing the size of the HIV-1 reservoir
are currently under investigation. Therefore, the discovery of a specific latently infected cell’s marker could
facilitate tailored interventions. CD32 was proposed as such by Descours et al. (Descours et al., 2017) but
has been heavily debated ever since (Bruel and Schwartz, 2018; Darcis et al., 2019). Here, we scrutinized the
relationship between the timing of ART initiation, T-cell immune activation/exhaustion, and reservoir char-
acteristics with regard to CD32 expression in tissues from humanized mice in order to delineate its use as a
surrogate marker of the viral reservoir.
Several groups have reported on humanized mice models of HIV-1 latency and their utility (Nischang et al.,
2012; Halper-Stromberg et al., 2014; Iordanskiy et al., 2015; Satheesan et al., 2018; Llewellyn et al., 2019).
We validated our humanized mice model of HIV-1 latency by first showing that the time to viral suppression
was shortened by early cART treatment as compared to late therapy which is similar to clinical observation
in humans (Ssebunya et al., 2017). Multiple studies have reported the benefits of early cART on immune
activation. Persistent chronic infections trigger increased expression of immune checkpoints such as
PD-1 and TIGIT on CD4+ and CD8+ T cells (Day et al., 2006; Trautmann et al., 2006), whereas cART
Figure 6. CD32 ExpressionWas Associated with High Expression Levels of Activation/Exhaustion Markers and Did Not Correlate with HIV-1 DNA
(A–C) Expression of HLA-DR (A), PD-1 (B), and TIGIT (C) in CD32-positive and negative CD4+ memory T cells from the spleen.
(D) Expression level of three combined activation markers (HLA-DR, CD38, and CD69) in flow sorted CD4+ memory T cells according to their CD32
expression. Geometric mean fluorescence intensity (GMFI) of activation markers plotted against the GMFI of CD32 from virally suppressed mice (mixed early
and late treatment conditions).
(E) Spearman correlation with fitted linear regression line (p value: 0.0004, R value: 0.6872). Statistical testing by non-parametric Mann-Whitney or Kruskal-
Wallis tests with multiple comparison Dunn’s correction. Two-tailed spearman correlation (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, ns,
nonsignificant test, p > 0.05).
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decreases PD-1 expression in parallel with reducing plasma VL after treatment onset (Cockerham et al.,
2014b). In our study, we observed a consistent decline of PD-1 and TIGIT expression that was only signif-
icant by early cART initiation when compared to untreated mice. The T-cell activation marker HLA-DR was
not significantly decreased by early or late cART regimen. Nevertheless, the recovery of total CD4+ T-cell
counts was rapid and successful in both treatment groups. These findings highlight that key aspects of HIV-
1 pathogenesis and cART treatment are recapitulated in the presented model.
It is accepted that early cART effectively reduces the size of viral reservoirs and preserves the functionality of
CD8 T cells, two conditions that might allow some individuals to achieve functional HIV-1 cure (Conway and
Perelson, 2015). Our findings underline the impact of treatment initiation’s timing on the level of total HIV-1
DNA spread in tissues as described in humans (Ananworanich et al., 2012; Laanani et al., 2015). Conversely,
time to viral rebound did not differ between early and late treated conditions, similarly reported by two
clinical studies that found also no prolonged control upon treatment cessation despite early ART initiation
(Gianella et al., 2015; Colby et al., 2018). Consequently, it could be argued that total HIV-1 DNA, when
sampled in tissues, is not a surrogate marker for time to viral rebound in contrast to human studies from
peripheral blood (Azzoni et al., 2013; Williams et al., 2014). Importantly, we observed that a portion of early
Figure 7. High-Dimensional Analyses Highlighted Different Activated/Exhausted Clusters Expressing CD32 in
Memory CD4 T Cells from the Spleen of Early and Late Treated Mice with cART
(A) FlowSOM hierarchical tree colored according to metaclusters.
(B) Metaclusters were annotated according to the heatmap shown in. Two-way hierarchical clustering of the 49 clusters
defined by FlowSOM and the median expression of the 9 markers indicated on the right of the heatmap. Median
expression across the three groups of mice is shown. Three viremic untreated mice (untreated mice, UT)) were kept four
weeks without treatment and four viremic mice were kept eight weeks; twenty-two mice were virally suppressed by
receiving early cART treatment (n = 12, ET mice) or receiving late cART treatment (n = 10, LT). The clusters significantly
different (p < 0.05) between four weeks and eight weeks of treatment are depicted on the bottom of the heatmap. A
significant increase or decrease is indicated in red or cyan, respectively.
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treated mice rebounded only transiently (26,67%) with subsequent ‘‘spontaneous’’ viral suppression,
whereas this ‘‘secondary control’’ phenomenon was not observed in the late treated group. This suggests
that early treatment increases the odds for delayed rebound, similar to a conclusion reached by the
CHAMP cohort (Namazi et al., 2018) that found higher percentage of post-treatment control (PTC) in early
treated individuals. The antiviral CD8+ T-cell response could play a role during PTC, but this was not
explored in greater detail because NSGmice lack antigen-specific T cells due to the absence of HLA-I pre-
sentation (Policicchio et al., 2016). Clearly, future studies should investigate the mechanisms of delayed
rebound in this model. Taken together, our data showed however that the viral reservoir is already estab-
lished and functional within one week after infection in most of the mice.
Figure 8. P24 Production after Latency Reversal Is Predominantly Found in CD32CD4+ Memory T Cells and Not
in the CD32+ Fraction
(A) Representative fluorescence activated cell sorting (FACS) plots of p24 staining in an untreated viremic mouse after five
weeks of HIV-1 infection and one ART-treated mouse, as well as a non-infected control mouse after PMA/ionomycin
reactivation. The strict gating assured no false positive signal.
(B) Intracellular p24 staining after PMA/ionomycin activation in ART-treated animals (n = 4) revealed that the highest
proportion of productive cells is CD32- and not CD32 +.
(C) The frequency of p24 producing cells is higher within CD32+CD4+ memory T cells than in CD32- cells.
(D) Expression of HLA-DR, CD38, and PD-1 at the surface of the reactivated cells producing p24 from graph B. Statistics
were performed using non-parametric testing. (*p < 0.05, ns, nonsignificant test, p > 0.05).
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A number of cellular HIV-1 reservoir markers have been proposed over the last years. Among those markers
the activation and immune checkpoint molecules HLA-DR, PD-1, TIGIT, but also CD32a (Cockerham et al.,
2014a; Fromentin et al., 2016; Descours et al., 2017; Gosselin et al., 2017; Hogan et al., 2018). According to
Descours et al., CD32a exhibited the promising trait to contain the replication-competent reservoir and to
enrich for about 103 fold enrichment for total HIV-1 DNA (Descours et al., 2017). These results have been
challenged by others, reporting either no (Abdel-Mohsen et al., 2018; Martin et al., 2018) or only marginal
enrichment (Bertagnolli et al., 2018; Pérez et al., 2018), for both HIV-1 DNA and replication-competent
proviruses. Such divergent findings were proposed to be due to technical tribulations during purification
of CD32+CD4+ T cells (Darcis et al., 2019), as several studies showed that CD32+CD4+ T cells contained
residual contamination by APCs which express high levels of CD32 (Martin et al., 2018; Osuna et al., 2018;
Pérez et al., 2018; Thornhill et al., 2019). Therefore, we established a flow cytometry strategy with strict
exclusion of B cells and monocytes (CD19 and CD14, respectively) as both cell types had been identified
as sources for non-T-cell contamination before (Martin et al., 2018; Osuna et al., 2018). This approach
enabled the identification of a CD32dim and not the CD32high population in a small fraction of CD4+
T cells. Using imaging cytometry, in both humanized mice and in HIV-1-infected patients, we found
that purified CD32+CD4+ T cells expressed CD32 on small, concentrated areas as previously reported
by Osuna et al. (Osuna et al., 2018) but without co-localization of monocytes or B cell markers (CD19
or CD20), thus excluding B-cell trogocytosis. Still, we detected a polarized and concentrated localization
of the CD32 protein on the membrane of CD4+ T cells that could come from other APCs or NK cells. We
detected CD32a mRNA expression on CD4+ memory T cells and a weak expression of CD32b mRNA as
well, whereas a pool of CD19+ and CD14+ population of B cells and monocytes expressed both CD32a
and CD32b mRNA. This suggests endogeneous expression of CD32a by CD4+ T cells similar to previous
findings (Holgado et al., 2018; Darcis et al., 2020). However, the latter results have to be interpreted with
caution as imaging cytometry data of ours and others (Osuna et al., 2018; Thornhill et al., 2019) unani-
mously challenge the origin of CD32 protein on CD4+ T cells. We assume that CD32b mRNA might orig-
inate from the attached CD32+ non-CD4+ T-cell entities or from trogocytosis-positive T cells expressing
higher level of activation markers, such as CD32a, due to more intensive T-cell/APC interaction. Taken
together, we clearly identified a non-monocyte or non-B-cell-induced portion, potentially due to trogo-
cytosis from other APC types or NK cells of CD32+CD4+ T cells or even from residual binding with plate-
lets known to express CD32a. These findings are in line with a recent study working on highly pure
CD32+CD4+ T cells (Darcis et al., 2020) and might advance the debate opened by many reports on
the source for the CD32 signal on CD4+ T cells (Martin et al., 2018; Osuna et al., 2018; Pérez et al.,
2018; Thornhill et al., 2019). Ultimately, our results open new questions about the exact origin of the
CD32 protein on CD4+ T cells.
In our study, we further focused on CD32 expression in memory CD4+ T cells (CD45RA) as this subset is
comprises central and effector memory T cells which are well known to contain the highest frequencies of
latently infected cells (Chomont et al., 2009; Bosque et al., 2011; Imamichi et al., 2014; Soriano-Sarabia
et al., 2014; Murray et al., 2016). As compared to other studies, we included both resting (HLA-DR- or
CD38- or CD69-) and non-resting (HLA-DR+ or CD38+ or CD69+) memory T cells. We found a significant
increase of CD32 expression between HIV-1-infected and uninfected mice in human lymph nodes only as
previously described (Bertagnolli et al., 2018). Importantly, a significant increase of about 0.85 log10
copies of CA HIV-1 DNA per millions cells in CD32+ when compared to CD32- memory T cells was
observed in virally suppressed mice. These findings are in agreement with results obtained from human
lymph nodes (Noto et al., 2018) but not with data derived from peripheral blood of HIV-1-infected pa-
tients (Abdel-Mohsen et al., 2018; Badia et al., 2018; Osuna et al., 2018; Pérez et al., 2018) unless the
CD32+ cells underwent multiple, consecutive rounds of purification to exclude B cells, monocytes, and
T-B cell doublets (Darcis et al., 2020). Despite CA HIV-1 DNA enrichment, there was no difference in
CA HIV-1 RNA between CD32+ and CD32CD4+ memory T cells from the spleen, suggesting that
CD32 labels cells with proviruses that are transcriptionally silent in tissues. However, the sample size
of our data is limited because the total RNA yield from sorted subsets was low, and this represents a
limitation of our study. Several studies from the lymph node and gut tissue reported the contrary (Ab-
del-Mohsen et al., 2018; Badia et al., 2018; Noto et al., 2018; Vasquez et al., 2019), but these findings
are in accordance with a recent study from highly purified blood-derived lymphocytes (Darcis et al.,
2020). Low transcription levels could be counterintuitive because we confirmed here, as others, that
CD32+CD4+ T cells express HLA-DR activation marker. Nevertheless, activated subsets can indeed
establish latent HIV-1 infection (Chavez, 2015; Lee et al., 2019).
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CD32 is a low affinity receptor for the Fc portion of IgG (FcgR) which represents a link between humoral and
cellular immunity and is highly expressed on myeloid cells and B cells. The functional role of CD32 on CD4+
T cells is not well understood yet. However, it has been suggested that immune complexes might
contribute to the continuation of chronic inflammatory responses by enhancing the activation of T cells
through CD32 (Holgado et al., 2018) that might maintain persistence of the latent HIV-1 reservoir. Impor-
tantly, the expression of HLA-DR, CD38, and CD69 was strongly increased in CD4+CD32+ memory T cells
from the tissues of cART-treated mice similar to recent studies from peripheral blood lymphocytes in hu-
mans (Badia et al., 2018; Wittner et al., 2018). Therefore, CD32+ CD4+ T cells might be more susceptible to
HIV-1 infection because they are activated in a first place. The increased levels of HIV-1 co-receptors CXCR4
and CCR5 on CD4+CD32+ T cells on healthy individuals argue in favor of this concept (Hogan et al., 2018;
Wittner et al., 2018). In addition, a recent study described tissue resident memory T cells from the cervical
mucosa expressing CD32 as enriched for several proteins associated to HIV-1 susceptibility (Cantero-Pérez
et al., 2019). CD32+CD4+ T cells could represent a pool of recently infected cells as drug penetration in tis-
sues can be insufficient to suppress viral replication (Lorenzo-Redondo et al., 2016; Estes et al., 2017; Roth-
enberger et al., 2019). Accordingly, CD32 expression is induced upon infection with HIV-1 in vitro (Descours
et al., 2017; Abdel-Mohsen et al., 2018; Badia et al., 2018). Furthermore, in human lymphoid and gut tissues,
CD32 mRNA expression was associated with persistent HIV-1 mRNA replication (Hogan et al., 2018; Noto
et al., 2018) which could indeed be explained by poor cART penetration unable to block residual HIV-1
replication. A relationship between active HIV-1 transcription and the CD32 gene has been already sug-
gested (Abdel-Mohsen et al., 2018; Vasquez et al., 2019). Whether up-regulation of CD32 mRNA is a direct
result of HIV-1 transcription or T-cell activation is still unknown. In this regard, our multidimensional reduc-
tion analysis revealed that CD32+CD4+ memory T cells have a high activation/exhaustion profile and clus-
tered phenotypically with distinct activated/exhaustedmemory T-cell subsets expressing HLA-DR, PD-1, or
TIGIT during suppressed viremia. This is in agreement with Badia et al. (2018) who has shown, following
ex vivoHIV-1 infection in activated and resting cells or in PBMCs fromHIV-1+ individuals, that CD32 expres-
sion is a marker of activation in a subset of CD4+ T cells both in uninfected controls and in HIV-1+ individ-
uals. These authors state that establishment of HIV-1 latency may be the consequence of infection in
CD4+T cells within a narrow window of time after activation. Thus, CD32 expression may signal a transition
state to or from a fully susceptible phenotype. Our data provide further evidence that CD32 labels a highly
activated/exhausted subset of memory CD4+ T cells that might favor subsequently an HIV-1 enrichment in
these cells.
Indispensable for the characterization of CD4+CD32+ T cells as latent HIV-1 reservoirs is to determine if
they contain replication-competent virus and can resume to viral production. The current gold stan-
dard, the quantitative viral outgrowth assay (qVOA), requires large amounts of cells. Given the rarity
of CD32+ CD4+ T cells in mice, we used intracellular p24 staining after in vitro latency reversal as re-
ported previously. We found a relative enrichment of p24 production in CD4+CD32+ memory T cells
similar in magnitude (about ten times) than the increase in CA HIV-1 DNA. However, overall
CD32+CD4+ T cells constituted only a small portion of the total p24 inducible cellular reservoir (<5%
of total p24 producing cells). Similar findings were reported in human lymph nodes (Abdel-Mohsen
et al., 2018). Clearly, the presence of p24 alone, although produced in an advanced stage of the
HIV-1 replication cycle, does not prove that the resulting viruses are correctly assembled, released,
and infectious. Furthermore, a single round of stimulation with PMA/ionomycin for 24 hr only does
not suffice to induce all replication-competent viruses (Ho et al., 2013; Laird et al., 2013). Unfortunately,
there is currently no assay that can accurately activate the entire replication-competent fraction. Near
full-length DNA sequencing does not take inducibility of viral gene transcription into account (Josefs-
son et al., 2013), and qVOA largely underestimates the replication-competent fraction (Ho et al., 2013).
Taken together, our data underline that CD4+CD32+ memory T cells are enriched for p24 production
after latency reversal but represent a small and negligible portion of the total inducible p24 producing
cells.
Finally, the clinical relevance of thememory CD32+ CD4+ T cells as long-term viral reservoir remains difficult
to estimate at this point in time. We observed a correlation of CD32 expression with the combined expres-
sion of all activation markers. Highly activated T cells are generally regarded as rather short lived (Chun
et al., 2005; Noto et al., 2018) but their contribution to HIV-1 persistence is widely accepted (Hatano
et al., 2013; Chavez, 2015; Deeks et al., 2016; Khoury et al., 2016; Lee et al., 2019). Consequently, for
HIV-1 infection to persist, activated reservoirs are required for continous replenishment either by ongoing
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viral replication (Martinez-Picado and Deeks, 2016) or by cellular proliferation (Chomont et al., 2009). Since
CD32 was shown to promote immune activation in CD4+ T cells in vitro (Holgado et al., 2018), it is tempting
to speculate that CD32 itself could induce and maintain activation leading to preferential vulnerability to
infection. The results of the cluster analysis reinforces this hypothesis by showing phenotypic similarities
and a high number of clusters in the memory CD32+ CD4+ T cells as compared to the CD32+ CD8+
T cells. This in turn would question its role as a long-lived reservoir. Finally, there was a significant upregu-
lation of PD-1 in CD32+ vs CD32- cells producing the inducible translation-competent virus after PMA stim-
ulation. Interestingly, Noto et al. have associated CD32+PD1+CD4+ T cells from lymph nodes with the high-
est levels of HIV-1 transcription (Noto et al., 2018).
In conclusion, the present work highlights that tissue-resident CD32+CD4+ memory T cells represent
different cellular subsets that are highly activated, enriched for total HIV-1 DNA, and produce P24 upon
latency reversal. Despite a relative enrichment, CD32+CD4+ T cells form an overall negligible portion of
the inducible P24 producing cells. Our findings support that CD32 expression is linked to immune activa-
tion in tissues which may explain the enrichment of CA HIV-1 DNA in CD32+CD4+ memory T cells. More
distinctive markers to target the silent and replication-competent HIV-1 reservoir are still needed.
Limitations of the study
We acknowledge several limitations to our study. The limited life span of humanized mice allowed cART
therapy for a maximum duration of eight weeks in our study design. This duration clearly differs from pa-
tient cohorts investigating HIV-1 latency after several years of suppressed viremia. Therefore, we cannot
exclude the impact of short-lived reservoirs with decay rates above eight weeks (Palmer et al., 2011) and
that the reservoir dynamics in CD32 + T cells derived from our latency model could be different than in pa-
tients with a longer treatment duration. This could potentially explain the lower relative enrichment in our
humanizedmice as compared to human PBMCs (Darcis et al., 2020). In addition, the quantity of blood avail-
able for longitudinal sampling and of human cells in tissues is also extremely limited in humanized mice.
Lastly, PMA/ionomycin’s activation used here to measure P24 producing cells might be able to induce
only a fraction of the cells harboring translation-competent viruses in the humanized mice. A significant
fraction of p24 producing cells does not also produce intact viral particles that are replication competent.
Therefore, we induce probably only one part of the translation-competent virus in our study. However, the
HIV-1 flow technique, by using 2 different P24 antibodies, provides a specific staining of the P24+ cells and
allows us to compare accurately between CD32+ CD4+memory T cells and their CD32-CD4+ counterpart,
the translation-competent virus induced by PMA/ionomycin.
Resource availability
Lead contact
Further information and requests for resources should be directed to and will be fulfilled by the Lead Con-
tact, Carole Devaux (caroledevaux@lih.lu).
Materials availability
The study did not generate any unique reagents.
Data and code availability
This published article includes all data sets generated or analyzed during this study.
METHODS
All methods can be found in the accompanying Transparent methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2020.101881.
ACKNOWLEDGMENTS
The authors would like to thank Jean-Marc Plesseria, Charlène Verschueren, Jean-Yves Servais, Christine
Lambert, and Quentin Etienne for their technical support. We thank Tuesday Lowndes for revising the
manuscript for English language. The study (HIV latency) was funded by a research grant from the Ministry
ll
OPEN ACCESS
14 iScience 24, 101881, January 22, 2021
iScience
Article
of Research, the Fondation Recherche sur le SIDA of Luxembourg, an educational grant from ViiV Health-
care Benelux, and the FWOgrant 1.8.020.09.N.00 (Linos L.V.). A.P. received a PhDAFR grant, F.V. aMobility
grant, and S.R. a PhD DTU PRIDE grant (Next-Immune) from The ‘‘Fonds National de la Recherche’’ in
Luxembourg. R.S. received a strategic basic research fund of the Research Foundation – Flanders (FWO,
1S32916N) and V.L. a Collen-Francqui Research Professor Mandate.
AUTHOR CONTRIBUTIONS
A.P. and F.V. setup the HIV-1 latency model in humanized mice, designed experiments, performed and
analyzed all experiments, drafted figures, and wrote the manuscript; S.R. performed experiments in hu-
manized mice and measured viral loads; A.M. performed and designed experiments in humanized mice
and drafted figures; I.G. performed flow cytometry, cell sorting, cell cultures, and Flow SOM analysis;
R.S. performed ddPCR assays for the measurement of CA HIV-1 RNA and CA HIV-1 DNA; D.G. setup the
viral load assay; V.G. analyzed and designed the experiments; C.A. designed and conducted the multidi-
mensional reduction analysis; H.F. performed flow SOM and cluster analysis; M.M. setup the humanized
mouse model of HIV-1 infection and provided cord blood cells; V.L. designed the ddPCR studies and
analyzed the results; S.-D.C designed, analyzed the data, supervised the study, and wrote the manuscript.
All authors participated in the preparation and editing of the manuscript.
DECLARATION OF INTERESTS
The authors declare that the research was conducted in the absence of any commercial or financial relation-
ships that could be construed as a potential conflict of interest.
Received: March 26, 2020
Revised: September 4, 2020
Accepted: November 25, 2020
Published: January 22, 2021
REFERENCES
Abdel-Mohsen, M., Kuri-Cervantes, L., Grau-
Exposito, J., Spivak, A.M., Nell, R.A., Tomescu, C.,
Vadrevu, S.K., Giron, L.B., Serra-Peinado, C.,
Genescà, M., Castellvı́, J., Wu, G., Del Rio
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SUPPLEMENTAL INFORMATION  
 
Transparent methods section 
 
NSG mice immune reconstitution, HIV-1 infection and treatment with cART 
NSG (NOD/LtSz-scid/IL2Rγnull) mice were purchased from Jackson Laboratory, USA. All animal experiments 
were performed in accordance with the Animal Welfare Structure of the Luxemburg Institute of Health (LIH) 
(protocol number: LRTV 1402) and complied with the national legislation and guidelines for animal 
experimentation. Juvenile (3-4 weeks of age) NSG mice were engrafted as previously published (Singh et al., 
2012). Briefly, mice were conditioned by two intraperitoneal Busulfan injections (20 mg/kg, Busilvex®) 24 
and 12 hours before transplantation. CD34+ hematopoietic stem cells were isolated from human cord blood, 
provided by the Blood Bank of the University Hospital (Liège, Belgium), by magnetic activated cell sorting 
(MACS), using the CD34+ progenitor cell isolation kit (Stem Cell Technologies, Vancouver, Canada). 
Subsequently 2x105 freshly isolated CD34+ cells were transplanted into each NSG mouse by intravenous 
injection. Mice were bled at 12 and 24 weeks post-transplantation to determine human immune cell 
reconstitution by flow cytometry.  
Animals with ≥ 20% of circulating human CD45+ cells at 24 weeks post-transplantation were infected by two 
intraperitoneal injections of a HIV-1 laboratory adapted strain (JRCSF, 10.000 TCID50) within 24 hours. 
Infection was monitored every 2 weeks on blood samples collected by submandibular bleeding for CD4+ T 
cell counting using flow cytometry analysis and for viral load measurement (see below). cART treatment was 
initiated 1 week (early treated) or 8 weeks (late treated) post infection and continued for a total of 8 weeks 
in both groups using a single tablet regimen of dolutegravir/abacavir/lamivudine (Triumeq®, ViiV Healthcare) 
provided in the drinking water. The tablets were crushed and dissolved in Sucralose MediDrop® (Clear H2O, 
Portland, USA) at the therapeutic concentration of 3.40 mg/ml. Drinking solution was refreshed twice per 
week and volumes were monitored to follow up consumption. At the end of the protocol, mice were 
anesthetized using a mixture of ketamine and xylazine, blood samples were collected via cardiac puncture 
and tissues were harvested for downstream analysis.  
 
Experimental design 
The study was structured into three arms (Figure 1). A first group of mice infected with HIV-1 received 
treatment from one week post infection on (early treated, n= 58). The second group was set on therapy at 
week seven post-infection (late treated, n=42) and a third group of HIV-1 infected mice never received 
2 
 
antiretroviral drugs (untreated, n=20). After eight weeks of cART treatment, animals were sacrificed (n= 43 
and 34 in early and late treated groups). Some animals was kept after cART was discontinued to measure 
time to viral detectability after treatment interuption. These groups of “viral rebound” were monitored for 
another six weeks (n=15 for early- and n=8 for late treated mice) or longer if they remained undetectable in 
plasma viral loads. Untreated animals were sacrificed at the matched time points with the early and late 
treated mice respectively (n=10 for each group). Non-infected and non-treated humanized mice (healthy 
animals) were added as controls when necessary for phenotyping. Monitoring of viral load upon HIV-1 
infection and under cART treatment was performed using absolute ddPCR measurement every two weeks.  
 
Organ collection, processing and isolation of cells 
Organs were collected at necropsy, washed in cold RPMI and processed immediately for cell isolation. Lymph 
nodes were dissected from the cervical, axillary, brachial and inguinal locations. Spleens and lymph nodes 
were gently disrupted in cold PBS using the plunger of a syringe. Bone marrow (BM) were obtained from 
tibias and femurs. Both ends of bones were opened and BM flushed out by short centrifugation at 600g 
during 30 seconds at room temperature. BM cells, splenocytes and lymph node suspensions were passed 
through 70 μm nylon cell strainers (BD Biosciences, Franklin-Lakes, New Jersey, USA) and centrifuged 10 min 
at 400g and 4°C. Splenocytes were resuspended in fresh ACK (Ammonium-Chloride-Potassium) solution (in 
house made) for 5 minutes to lyse red blood cell followed by two washes with RPMI 1640 (GIBCO Life 
technologies, Thermo Fisher Scientific). 
Quantification of HIV-1 plasma and tissues viral load 
Plasma viral load was measured by an in-house droplet digital PCR (ddPCR) assay. Input volumes of 100 µl 
were used for RNA extraction using the MagNA Pure Compact nucleic acid isolation kit (Roche, Basel, 
Switzerland) according to the manufacturer’s protocol by diluting 30 µl of mice plasma in 70 µl of PBS. The 
PCR reaction mixture was loaded into the Bio-Rad QX200™ Droplet Generator (Bio-Rad laboratories, 
Hercules, CA, USA). Emulsification droplets were formed following the manufacturer’s instructions. Primers 
and probes were designed as reported previously (Jones et al., 2014). Total RNA was amplified by ddPCR 
PalmerddPCR Advanced kit for Probes. Droplets were analyzed on QX200 Droplet Reader (BioRad). The limit 
of detection is 235 copies/ml (33). Data were analyzed with the QuantaSoft software (Bio-Rad laboratories, 
Hercules, CA, USA). To measure HIV-1 RNA in different tissues, twelve humanized mice (as described above) 
were infected by two intraperitoneal injections of HIV-1 (JRCSF, 10.000 TCID50) within 24 hours. One week 
after infection, six mice were sacrificed for downstream analysis and six mice started cART as previously 
described and continued for a total of eight weeks. Plasma viral load was monitored every 2 weeks on blood 
samples collected by submandibular bleeding. At the end of cART treatment, mice were sacrificed for organ 
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collection and all organs were processed immediately for cell isolation using the NucleoSpin® Tissue kit 
(Macherey-Nagel, Düren, Germany). 300uL lysis buffer was used for RNA extraction in the spleen and the 
bone marrow and 100uL of lysis buffer was used for the Lymph nodes. Input volumes of 100 µl were used for 
plasma RNA extraction using the QIAamp Vrial RNA Mini Kit (Qiagen) according to the manufacturer’s 
protocol. Plasma and organ viral loads were measured by our in-house droplet digital PCR (ddPCR) assay as 
described above.  
 
Quantification of total Cell-associated (CA)-HIV-1 DNA and CA-HIV-1 RNA from 
human CD45+ cells 
Human CD45+ cells from organs were purified by positive selection using magnetic beads (CD45 MicroBeads, 
Miltenyi Biotec, Bergisch-Gladbach, Germany) following the instructions of the manufacturer and pelleted. 
Total DNA was extracted from spleen, lymph nodes, lungs and bone marrow cells by manual extraction using 
the NucleoSpin® Tissue kit (Macherey-Nagel, Düren, Germany) according to manufacturer’s instructions. 
Aliquots of eluted samples were frozen at −80 °C un l total CA HIV-1 DNA quantification by ddPCR as 
previously reported (Rutsaert et al., 2019). RNA was isolated from human CD45+ cells using the innuPrep RNA 
Mini Kit 2.0 (Westburg, Berlin, Germany), then reverse transcribed into cDNA using qScript cDNA SuperMix 
(Quanta bio, Beverly, Massachusetts, USA) in a total volume of 20µl according to manufacturer’s protocol. 
CA HIV-1 RNA was measured by ddPCR (Bio-Rad, Hercules, California) in triplicates as previously described 
(Van Hecke et al., 2019) with the primers/probe as described above for HIV-1 DNA. Three reference genes 
(B2M, ACTB, and GAPDH) per cDNA samples were assessed by qPCR to normalize for RNA input. Copies of 
CA-RNA were divided by the geometric mean of the reference gene related to the theoretical number of cells 
(expressed in copies per million cells). 
 
Flow cytometry, cell sorting and image cytometry 
Detailed phenotyping of human B and T cells was performed using 2x10^6 single cells from each organ. Cells 
were washed with PBS containing 1%FBS (Gibco™, Thermo Fisher Scientific, Waltham, Massachusetts, USA) 
and stained for 30 min at 4°C with fluorochrome-labeled monoclonal antibodies (human reactivity if not 
indicated differently): CD4-BUV395 (SK3), CD3-BUV496 (UCHT1), CD8-BUV805 (SK1), CD279-BV421 
(EH12.2H7), CD28-BV605(CD28.2), CD27-BV650(M-T271), CD197-PECF-594 (150305), murineCD45RO-PECy5 
(30-F11) from BD Biosciences, HLA-DR-BV510 (L243), CD127-BV711(HIL-7R-M21), CD32-PE (FUN-2), TIGIT-
APC (A151536) from Biolegend (San Diego, CA, USA) and LIVE/DEAD fixable Near-IR cell dye (Thermo Fisher 
Scientific). Cells were fixed for 1h at 4°C using 1X BD Lysing solution (BD Biosciences, Cat n°: 349202) before 
acquisition. Samples were acquired on a FACS Fortessa SORP 5 laser instrument (BD Biosciences) and 
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analyzed with the Kaluza (version 2.1, Beckman Coulter, Brea, California, USA) and Flow Jo (version 10, BD 
Biosciences) softwares. A Two-way cell sorting was done by staining single cells derived from organs with 
CD3-BV510 (UCHT-1), CD4-PECy7 (RPA-T4), CD8-BV711 (RPA-T8), CD19-APC (HIB19), CD14-APC (61D3), 
CD45RA-FITC (HI100), murineCD45-PECy5 (30-F11) (BD Biosciences) and CD32-PE (FUN-2) (Biolegend), and 
LIVE/DEAD fixable Near-IR cell dye (Thermo Fisher Scientific). CD4+CD45RA- memory T cells were sorted 
based on their expression of CD32 into positive and negative subsets using BD Influx instrument (BD 
Biosciences). For visualization of sorted cells (CD32+CD4+ T cells and B cells) sorting was executed with five 
laser ARIA cell sorter (BD Biosciences) and purified populations were acquired with the ImagestreamX (Amnis 
Corporation, Seattle, WA, USA). mCD45-FITC (30-F11), CD4-PE-CF594 (RPA-T4), CD20-BV421 (2H7), CD3-
BV510 (UCHT1), CD32-APC (FLI8.26) (BD Biosciences), CD19-PE (SJ25C1) (Biolegend), CD14-PECy5 (61D3) 
(eBiosciences) and LIVE/DEAD fixable Near-IR cell dye (Thermo Fisher Scientific).The detailed gating strategy 
for all cytometry application on CD4+ T cells for strict exclusion of CD19, CD14 and doublets is given in 
supplemental Figure 3. PBMCs from two HIV-1 infected patients under cART for more than 2 years  were also 
analyzed as previously described. The study was approved by the Ethical Committee of Luxembourg 
(201307/10).  The two patients provided their written informed consent to participate in the study.   
 
Measurement of CD32a and CD32b mRNA 
To determine the CD32 isoform expressed in the memory CD4 + T cells, BM cells and splenocytes from 3 mice 
infected with HIV-1 and treated early with cART during 8 weeks were isolated as described above. Nucleic 
acids were extracted from sorted CD32+CD45RA-CD4+ T cells, CD32-CD45RA- CD4+ T cells and a pool of CD14+ 
and CD19+ cells from the spleen and the bone marrow using Nucleospin RNA XS (Marcherey Nagel, Germany) 
and treated with DNase (DNA-free kit, Thermo Fisher Scientific) following manufactor’s instructions. For the 
CD32+CD45RA- CD4+ T cell fraction, cells from the 3 spleens or from the 3 BM were pooled before RNA 
extraction whereas the nucleic acids from the two other fractions of cells (CD45RA- CD4+CD32- T cells and a 
pool of CD14+ and CD19+ cells) were extracted for each mouse individually. Reverse transcription was 
executed using the High-Capacity RNA-to-cDNA™ Kit (Thermo Fisher Scientific) according to manufacturer’s 
instructions. Cellular mRNAs were quantified using TaqMan™ Gene Expression Assays (all from Thermo Fisher 
Scientific): CD32A: Hs01013401_g1, CD32B: Hs00269610_m1, GAPDH: Hs02758991_g1 using Real-Time PCR 
(ABI 7500 Fast, Thermo Fisher Scientific). Non-template control wells were included in every qPCR run and 
were consistently negative.  
 
Cluster analysis and multidimensional reduction  
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To investigate the relationship between CD32 expression and the activation status of CD4+ and CD8+  T cells, 
three groups were without treatment (n=8), early treatment (n=12) and late treatment (n=10). The three 
groups of mice were phenotyped at four weeks and eight weeks of HIV-1 infection or four and eight weeks 
of treatment. Splenocytes were harvested and flow cytometry was performed as described above. Between 
207 and 793506 live CD3+CD14-CD19- T cells were gated for each sample using FlowJo (BD Bioscience, version 
10.7). Live CD3+CD14-CD19- T cells were exported as FCS files and uploaded into the Cytobank environment 
(Beckman Coulter). After proper scaling for each marker (Mazza et al., 2018) the FlowSOM algorithm (Van 
Gassen et al., 2015) was used to generate 49 clusters grouped in ten metaclusters. FlowSOM parameters 
were as follow: 4 millions of proportionally selected events; clustering channels: CD4, CD8, CD145RA, CCR7, 
TIGIT, PD1, HLADR, CD32 and CD38; iteration number: 10. Hierarchical analysis, heatmap and statistical 
analyses (Kruskal Wallis tests) were done in Qlucore version 3.6 (Lund, Sweden). 
 
Quantification of translation-competent viral reservoirs 
The HIV-1 Flow assay was used as previously described (Pardons et al., 2019) to quantify the amount of the 
p24 producing HIV-1 reservoir in human CD4 + CD32 + versus CD4 + CD32 – T cells. Briefly, cells were harvested 
from spleen and bone marrow of HIV-1 infected cART suppressed mice (late protocol, as described above) 
and cultured in RPMI (10% Fetal Bovine Serum and 2% Penstrep) supplemented with antiretroviral drugs 
(200nM raltegravir, 200nM lamivudine). A protein transport inhibitor (Golgi Plug, BD Biosciences) was added 
according to manufacturer’s instruction 1 hour before stimulation and maintained during stimulation with 
PMA (162nM/mL) and Ionomycin (1μg/mL) for 24 hours. Cells were stained for surface markers and the 
intracellular p24 protein (anti-p24 PE, clone: KC57, Beckmann Coulter and anti-p24 APC, clone: 28B7, 
MediMabs, Canada) using the BD Cytofix/Cytoperm staining kit (BD Biosciences). Extracellular expression of 




Statistical analysis was performed using GRAPHPAD PRISM software. Groups were compared using 
nonparametric Mann-Whitney U test or Kruskal Wallis with Dunn correction for multiple comparison. A p-
values < 0.05 was considered to be significant. Two-tailed Spearman correlation coefficient was calculated 
for several comparisons (r and p values indicated on respective graphs). Mantel-Cox rank test was applied 
for Kaplan Meyer curve comparison. Paired or unpaired Wilcoxon signed-rank test were used when indicated. 
For all statistical testings a p-values < 0.05 was considered to name as significant in the text. The following 
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symbols were used as abbreviations for results of statistical significance testing on figures, p values: * ≤ 0.05, 







Singh, M. et al. (2012) ‘An improved protocol for efficient engraftment in NOD/LTSZ-SCIDIL-2RγNULL mice 
allows HIV replication and development of anti-HIV immune responses’, PLoS ONE, 7(6).  
Jones, M. et al. (2014) ‘Low copy target detection by Droplet Digital PCR through application of a novel open 
access bioinformatic pipeline, “definetherain”’, Journal of Virological Methods, 202, 46–53.  
Rutsaert, S. et al. (2019) ‘Evaluation of HIV-1 reservoir levels as possible markers for virological failure during 
boosted darunavir monotherapy’, The Journal of antimicrobial chemotherapy.  
Van Hecke, C. et al. (2019) ‘Early treated HIV-1 positive individuals demonstrate similar restriction factor 
expression profile as long-term non-progressors’, EBioMedicine.  
Mazza, E. M. C. et al. (2018) ‘Background fluorescence and spreading error are major contributors of 
variability in high-dimensional flow cytometry data visualization by t-distributed stochastic neighboring 
embedding’, Cytometry Part A.  
Van Gassen, S. et al. (2015) ‘FlowSOM: Using self-organizing maps for visualization and interpretation of 
cytometry data’, Cytometry Part A.  
Pardons, M. et al. (2019) ‘Single-cell characterization and quantification of translation-competent viral 








Figure S1 related to Figure1. Viral rebound after cART interruption in early versus late treated mice and 
HIV RNA content in tissues from viremic and virally suppressed mice. 
Individual values of HIV-1 RNA copies in log10 scale per ml of blood plasma over time after treatment 
interruption in light grey lines in mice treated early after 1 week of HIV-1 infection (A) and in mice treated 
late (B) (Group mean in bold black line). Four mice treated early reached undetectable viral load four or six 
weeks after treatment interruption. C. HIV-1 RNA content in different tissues of viremic and virally 
suppressed humanized mice. Twelve mice were infected with HIV-1 by two intraperitoneal injections of HIV-
1 JRCSF (10.000 TCID50) within 24 hours. Six mice were sacrificed one week after infection (viremic mice) 
and six mice were treated with cART during 8 weeks after one week of infection and sacrificed to measure 
viral load (VL, HIV-1 RNA) in the bone marrow (BM), in the lymph nodes (LN) and in the spleen (SP). One 
mouse did not reach HIV-1 RNA undetectability after 8 weeks of treatment. In the BM, HIV-1 RNA is not 
detectable after 8 weeks of cART whereas a mean of 100 copies/ng of total RNA was measured in the lymph 
nodes and in the spleen of the early treated mice. D). Plasma viral load of the viremic and virally suppressed 
humanized mice. Statistical testing was done using non-parametric Kruskal Wallis test with multiple 







Figure S2 related to Figure 2. CD4+ T cells were preserved by ART in the spleen of humanized mice.  
Relative percentage of CD4+ T cells (A) and CD27 expression in CD4+ T cells (B). Statistical testing was done 
using non-parametric Kruskal Wallis test with multiple comparison Dunn’s correction (**p< 0.01, *** p< 







Figure S3 Related to Figures 4 and Figures 5. Flow cytometry gating strategy for the phenotypic 
investigation of CD32+CD4+ T cells. 
Following a lineage gating strategy (top layer) we strictly gated on singlet cells and further excluded potential 
contaminations by gating on negative events for CD14 and CD19, leading to a highly pure CD32 dim T cell 
population. In contrast clear doublet cells of T and B cells are detected leading to a CD32 Bright population in 






Figure S4 Related to Figures 4 and 5. Purity of CD4+CD32+ T cells before and after sorting from splenocytes 
of humanized mice using the established gating strategy (Figure S3).   
Representative plots depicting the expression of CD14/CD19 and CD4 in CD4+CD32+ T cells sorted from 
splenocytes of humanized mice. Cells were gated on lymphocytes (singlets and live cells) before (Pre-Sorting) 
and after (Post-Sorting) cell sorting of CD4+CD32+ T cells. The purity was assessed on four different mice 










Figure S5 related to Figure 5. Longitudinal expression of CD32 in CD4+ memory T cells from spleen 
Representative FACS plots of CD32 expression on B cells and CD4+ memory T cells (A). CD32 expression on 
CD4+ memory T cells from spleen did not differ significantly over time between treatment groups (B). Three 
groups of mice were infected with HIV-1: viremic, untreated mice (n= 12), mice receiving early cART 








Figure S6 Related to Figure 5. CD32 expression on memory CD4+ T cells from different tissues is similar 
between the different treatment groups  
Expression of CD32 on CD4+CD45RA- T cells in blood (A), spleen (B), bone marrow (C) and lymph nodes (D) 
from flow sorted cells of healthy uninfected mice (n=8), early treated mice (n= 8), late treated mice (n=12), 
and untreated mice (n= 13). Statistical testing was performed using non-parametric Kruskal Wallis test with 







Table S1 Related to Figure S6. Descriptive statistics of CD32+CD4+CD45RA- T cells from different tissues given in Figure 
S6 related to Figure 5. 
 
  Groups of mice   
Tissues Healthy Early Treated Late Treated Untreated 
Blood     
Number of mice 8 11 12 4 
Mean  1.464 1.845 2.838 2.83 
Std. Deviation 1.001 0.7517 2.172 1.876 
Std. Error of Mean 0.3539 0.2266 0.6271 0.9378 
Spleen     
Number of mice 8 12 15 10 
Mean  0.9113 0.855 1.528 1.407 
Std. Deviation 0.5946 0.7943 1.494 0.963 
Std. Error of Mean 0.2102 0.2293 0.3857 0.3045 
Bone marrow     
Number of mice 8 8 12 7 
Mean  0.5188 2.398 2.455 2.776 
Std. Deviation 0.3728 2.499 1.88 1.879 
Std. Error of Mean 0.1318 0.8834 0.5426 0.7103 
Lymph nodes     
Number of mice 8 9 11 13 
Mean  0.315 0.5778 1.468 1.482 
Std. Deviation 0.2398 0.5523 1.681 0.8409 
Std. Error of Mean 0.847 0.1841 0.5068 0.2332 
 
 
